This study identifies HSG as a critical tumor suppressor in malignant meningioma that restrains tumor aggressiveness by dampening the Wnt/β-catenin cascade. These novel findings highlight the HSG-Wnt/β-catenin axis as a promising therapeutic target, offering new translational strategies for the management of this highly aggressive intracranial tumor.

1 day ago

Journal • IO biomarker

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9)

Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT). (PubMed, BMJ Open)

Subcutaneous schwannomas of the skin (CS) are common in the NF2 population.This trial involves the repurposing of medications already licensed for HIV-ritonavir and lopinavir (Kaletra and Norvir)-that have been shown to reduce tumour growth by reducing cell proliferation in human schwannoma and meningioma tumour cell cultures...Following analysis of trial data, the trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences. ISRCTN10422213.

3 days ago

Journal

NF2 (Neurofibromin 2)

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma. (PubMed, Front Oncol)

The hematological parameters remained stable for the whole period of observation. The presented clinical case report describes a unique positive experience on the use of [225Ac]Ac-PSMA-617 therapy in mCRPC and brain meningioma, thus allowing us to expand our understanding of PSMA RLT as a method for the treatment of not only prostatic tumors but also tumors of non-prostatic locations.

4 days ago

Journal

FOLH1 (Folate hydrolase 1)

FOLH1 expression

Triple metachronous primary brain tumors: sequential occurrence of astrocytoma, atypical meningioma, and high-grade glioma without radiotherapy exposure. Illustrative case. (PubMed, J Neurosurg Case Lessons)

This case underscores that metachronous collision tumors can arise without radiotherapy, necessitating histopathological and molecular integration for accurate diagnosis. Long-term vigilance is critical for detecting sequential tumors, and shared microenvironments or genetic pathways may underlie tumorigenesis. Comprehensive profiling aids in clarifying pathogenesis and guiding management. https://thejns.org/doi/10.3171/CASE26149.

4 days ago

Journal

IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NOTCH1 (Notch 1) • NCOR2 (Nuclear Receptor Corepressor 2) • CHD4 (Chromodomain Helicase DNA Binding Protein 4) • GFAP (Glial Fibrillary Acidic Protein)

IDH2 R172

Stratification by Ki-67 Labeling Index Increases Specificity of p16INK4a Expression as a Surrogate Marker for CDKN2A Inactivation in Meningioma. (PubMed, Mod Pathol)

Using Ki-67 as a surrogate marker for tumor aggressiveness, we identified a threshold of 5% in tumors with low p16 expression as a sensitivity cutoff for predicting CDKN2A inactivation, suggesting the subset of meningiomas with a higher labeling index could benefit from further molecular validation while the subset with p16hi expression are low yield to profile for CDKN2A status. Our findings support the clinical utility of Ki-67 and p16 expression as cost-effective screening tools to flag potentially aggressive meningiomas, particularly in resource-constrained settings.

4 days ago

Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)

CDKN2A deletion

KRT18 promotes the high-grade meningioma proliferation by interacting with LDHA to activate glycolysis and the PI3K/AKT signaling pathway. (PubMed, Cancer Lett)

It also functions as an oncogene by activating glycolysis and the PI3K/AKT signaling pathway through interaction with LDHA. Additionally, Fluvastatin is identified as a candidate for drug repurposing in high-grade meningioma.

4 days ago

Journal

LDHA (Lactate dehydrogenase A) • KRT18 (Keratin 18)

Anaplastic meningioma with abundant extracranial metastases: a case report. (PubMed, J Med Case Rep)

This report describes an anaplastic meningioma with multiple extracranial metastases. The extensive multiorgan involvement and rapid progression by the autopsy confirmation distinguish this as a rare case with markedly greater malignancy than typically reported.

6 days ago

Journal

PGR (Progesterone receptor)

Exceptional response of radiotherapy-naïve cranial meningiomas to dual immune checkpoint blockade in BAP1 tumor predisposition syndrome. (PubMed, Neurooncol Adv)

In sporadic meningiomas, BAP1 alterations are rare but define an aggressive molecular subset with poor outcomes. Here, we describe a patient with BAP1-TPDS and multifocal cranial meningiomas who experienced exceptional radiographic regression of her tumors while receiving dual immune checkpoint blockade for metastatic uveal melanoma.

6 days ago

Journal • Checkpoint inhibition • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker

BAP1 (BRCA1 Associated Protein 1)

A proteogenomic RNA processing mechanism drives sex differences in meningioma. (PubMed, Res Sq)

These findings reveal therapeutic strategies and a PR target gene biomarker that may improve outcomes for patients. More broadly, we elucidate an estrogen receptor-independent mechanism of PR expression that underlies sex differences in cancer.

7 days ago

Journal

ER (Estrogen receptor)

FOXC1 as a molecular predictor of postoperative peritumoral edema resolution in meningiomas. (PubMed, J Neurooncol)

Higher FOXC1 expression was independently associated with greater postoperative PTBE resolution. These findings require validation in larger independent cohorts before clinical implementation.

8 days ago

Journal

FOXC1 (Forkhead Box C1)

Malignant Progression of Meningiomas: Occurrence, Outcomes, and Underpinning Factors. (PubMed, World Neurosurg)

Malignant progression in meningiomas appears to reflect a process of clonal evolution shaped by genomic instability and therapeutic selection pressures. In this context, the observed association between irradiation and adverse outcomes underscores the need to critically reassess its role, while surgical resection remains the cornerstone of management.

8 days ago

Journal

TP53 (Tumor protein P53) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH2 (Notch 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • NOTCH3 (Notch Receptor 3) • FANCG (FA Complementation Group G)